ProCE Banner Activity

Advances in MDS and MPN From ASH 2019

Conference Coverage
Clinical Thought
In this commentary, Rami S. Komrokji, MD, provides an overview of key MDS and MPN studies from ASH 2019.

Released: March 09, 2020

Expiration: March 08, 2021

Share

Faculty

Rami S. Komrokji

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Rami S. Komrokji, MD, has disclosed that he has received consulting fees from Celgene, Daiichi Sankyo, Jazz, Novartis, and Pfizer.